Education
About Us
Working with TipRanks
Follow Us
Orion (0M2O) (DE:OFK)
:OFK
OFK Stock Chart & Stats
Day’s Range― - ―
52-Week Range€36.49 - €57.44
Previous CloseN/A
Volume100.00
Average Volume (3M)9.00
Market Cap
€7.78B
Enterprise ValueN/A
Total Cash (Recent Filing)€259.40M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)22.3
Beta0.64
Next Earnings
Jul 18, 2025EPS Estimate
0.45Next Dividend Ex-Date
Oct 15, 2025Dividend Yield2.94%
Share Statistics
EPS (TTM)2.47
Shares Outstanding108,683,530
10 Day Avg. Volume5
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio4.10
Price to Book (P/B)7.41
Price to Sales (P/S)0.00
P/FCF Ratio44.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Bulls Say, Bears Say
Bulls Say
EarningsNubeqa is expected to drive consensus EPS upgrades, improving Orion's ability to raise the dividend, which is crucial for local investors.
Product PortfolioOpevesostat (ODM-208) could sustain growth into the 2030s, with potential peak sales of €1.1 billion and Orion eligible to receive $1.6 billion in milestones.
Sales OutlookNubeqa's peak sales are projected to reach €1.3 billion, backed by Bayer's optimistic outlook, positive doctor feedback, and strong IQVIA script trends.
Bears Say
CompetitionNubeqa faces competition from Xtandi and Erleada, although it is preferred by doctors for better tolerability and flexibility in use with comorbidities.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
5.45%
Mutual Funds
― Other Institutional Investors
82.06% Public Companies and
Individual Investors
OFK FAQ
What was Orion (0M2O)’s price range in the past 12 months?
Orion (0M2O) lowest stock price was €36.49 and its highest was €57.44 in the past 12 months.
What is Orion (0M2O)’s market cap?
Orion (0M2O)’s market cap is €7.78B.
When is Orion (0M2O)’s upcoming earnings report date?
Orion (0M2O)’s upcoming earnings report date is Jul 18, 2025 which is in 63 days.
How were Orion (0M2O)’s earnings last quarter?
Orion (0M2O) released its earnings results on Apr 23, 2025. The company reported €0.44 earnings per share for the quarter, beating the consensus estimate of €0.393 by €0.047.
Is Orion (0M2O) overvalued?
According to Wall Street analysts Orion (0M2O)’s price is currently Overvalued.
Does Orion (0M2O) pay dividends?
Orion (0M2O) pays a Annually dividend of €1.629 which represents an annual dividend yield of 2.94%. See more information on Orion (0M2O) dividends here
What is Orion (0M2O)’s EPS estimate?
Orion (0M2O)’s EPS estimate is 0.45.
How many shares outstanding does Orion (0M2O) have?
Orion (0M2O) has 108,683,530 shares outstanding.
What happened to Orion (0M2O)’s price movement after its last earnings report?
Orion (0M2O) reported an EPS of €0.44 in its last earnings report, beating expectations of €0.393. Following the earnings report the stock price went up 3.824%.
Which hedge fund is a major shareholder of Orion (0M2O)?
Currently, no hedge funds are holding shares in DE:OFK
---
Company Description
Orion (0M2O)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
---
OFK Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---